Kura Oncology names Jennifer Fulk as chief financial officer

Kura Oncology, Inc. disclosed in an 8-K filing that effective September 8, 2026, the Board of Directors appointed Jennifer Fulk as the company's Chief Financial Officer, principal financial officer, replacing Troy E. Wilson solely with respect to that role, and principal accounting officer, replacing Thomas Doyle solely with respect to that role.¹

Fulk, age 49, most recently served as Chief Financial Officer of Soleno Therapeutics, Inc., from March 2026 to May 2026.¹ Earlier in her career, she served as Chief Operating Officer and Chief Financial Officer of 120Water, Inc., from September 2024 to October 2025 and as Chief Financial Officer of Talkspace, Inc., a publicly traded virtual behavioral healthcare company, from July 2021 to May 2024.¹ Before that, Ms. Fulk spent more than 15 years at Eli Lilly and Company in finance executive roles, including as Chief Financial Officer, U.S. Bio-Medicines; Vice President, Investor Relations; Vice President, Global Finance and Integration, Elanco; and Chief Financial Officer, Lilly Germany, Austria, and Switzerland.¹ She holds a Bachelor of Science in Information Systems and a Master of Business Administration from Indiana University.¹

Under her employment agreement dated September 8, 2026, Fulk is entitled to an annual base salary of $550,000, eligible for an annual discretionary bonus of up to 45% of her base salary, and entitled to an option for 450,000 shares plus a one-time performance-based restricted stock unit award covering 173,438 shares.¹ The stock option vests over four years, with 25% vesting on the one-year anniversary and 1/48th vesting monthly thereafter,¹ while the PSU vests in six installments tied to net product revenue, clinical development and regulatory approval milestones set by the Board.¹

The agreement also outlines severance terms. Outside a change-of-control window, a qualifying termination entitles her to 12 months of base salary, up to 12 months of COBRA premiums, and an extended option exercise period.¹ If termination occurs around a "Corporate Transaction," she would instead receive 18 months of base salary, 150% of her target bonus, 18 months of COBRA premiums, full acceleration of equity awards at target, and an extended exercise period.¹ Her employment is at-will and may be terminated by either party with or without cause.¹